Combination drug therapy for relapsed or resistant large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma or a similar type of B-cell lymphoma.
- Your lymphoma has come back or not responded after at least one prior treatment, unless you received CAR T-cell therapy and had a specific scan score between 30 and 90 days after that treatment.
- You must have at least one tumor that can be measured on a CT or PET scan (size 1.5 cm or larger).
- You are 18 years or older.
- Your kidney, liver, and blood counts (like white cells and platelets) must be within certain limits as assessed by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This study tests a combination of four drugs (sonrotoclax, glofitamab, gemcitabine, and oxaliplatin) for people with large B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Hear when a new Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.